Innovent Biologics, Inc. (HKG:1801)

Market Cap	140.77B
Revenue (ttm)	10.03B
Net Income (ttm)	-100.70M
Shares Out	1.71B
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	287.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,078,853
Average Volume	25,415,948
Open	81.75
Previous Close	82.35
Day's Range	80.25 - 83.90
52-Week Range	28.65 - 88.55
Beta	0.25
RSI	60.70
Earnings Date	Jun 11, 2025

About Innovent Biologics

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injec...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5,659
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1801

Financial Performance

In 2024, Innovent Biologics's revenue was 9.42 billion, an increase of 51.82% compared to the previous year's 6.21 billion. Losses were -94.63 million, -90.79% less than in 2023.

Financial numbers in CNY